

Jauniaux Eric (Orcid ID: 0000-0003-0925-7737)  
Coutinho Conrado Milani (Orcid ID: 0000-0003-1966-0466)  
Khalil Asma (Orcid ID: 0000-0003-2802-7670)  
D'Antonio Francesco (Orcid ID: 0000-0002-7546-8025)

## **Urological complications in women undergoing surgery for placenta accreta spectrum disorders: systematic review and meta-analysis**

A. Lucidi<sup>1</sup>, E. Jauniaux<sup>2</sup>, A. M. Hussein<sup>3</sup>, C. Coutinho<sup>4</sup>, S. Tinari<sup>1</sup>, A. Khalil<sup>5,6</sup>, A. Shamshirsaz<sup>7</sup>, J. Palacios-Jaraquemada<sup>8</sup> and F. D'Antonio<sup>1</sup>

1. Center for Fetal Care and High-Risk Pregnancy, Department of Obstetrics and Gynecology, University of Chieti, Chieti, Italy
2. EGA Institute for Women's Health, Faculty of Population Health Sciences, University College London, London, UK
3. Department of Obstetrics and Gynecology, University of Cairo, Cairo, Egypt
4. Department of Gynecology and Obstetrics, Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, São Paulo, Brazil
5. Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute, St George's University of London, London, UK
6. Fetal Medicine Unit, Liverpool Women's Hospital, University of Liverpool, Liverpool, UK
7. Boston Children Hospital, Harvard Medical School, Boston, MA, USA
8. CEMIC University Hospital and School of Medicine, Universidad de Buenos Aires, Buenos Aires, Argentina

**Corresponding author:** Prof. F. D'Antonio

Centre for fetal care and high-risk pregnancy

Center for Fetal Care and High-Risk Pregnancy, Department of Obstetrics and Gynecology, University of Chieti, Chieti, Italy

E-mail: francesco.dantonio@unich.it

**Short title:** Urological complication in placenta accreta spectrum

**Keywords:** Placenta accreta spectrum disorders; urological complication; hysterectomy; Cesarean section

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the [Version of Record](#). Please cite this article as doi: [10.1002/uog.26299](https://doi.org/10.1002/uog.26299)

## **CONTRIBUTION**

### **What are the novel findings of this work?**

The present systematic review provides a comprehensive evaluation of the incidence of urologic complications associated with surgery for PAS. Patients placenta percreta and those requiring an emergent delivery had the highest incidence of urologic complications, mainly cystotomy.

### **What are the clinical implications of this work?**

The high prevalence of urologic of women with PAS disorders highlight the need for a multidisciplinary approach of these anomalies in centres with high expertise in surgical management of PAS.

## ABSTRACT

**Objective:** To report the occurrence of urologic complications in women undergoing surgery for placenta accreta spectrum (PAS) disorders.

**Methods:** Medline, Embase and Cochrane databases were searched electronically up to 1<sup>st</sup> of November 2022. Studies reporting cohort on surgical management and outcome of PAS. Two independent reviewers performed the data extraction using a predefined protocol and assessed the risk of bias using the Newcastle-Ottawa scale for observational studies, with difference agreed by consensus. The primary outcome was the overall occurrence of urologic complications in women undergoing surgery for PAS. Secondary outcomes were overall cystotomy, intentional cystotomy, unintentional cystotomy, ureteral damage, ureteral fistula, vesicovaginal fistula. All these outcomes were explored in the overall population of patients undergoing hysterectomy for PAS disorders. In addition, we performed sub-group analyses according to the severity of PAS at histopathology (placenta accreta/increta and percreta), type of intervention (planned vs emergency), ureteral stent placing and number of cases per year. Random-effect meta-analyses of proportions were used to analyze the data.

**Results:** Sixty-two studies were included. Urologic complications occurred in 15.29% (95% CI, 13.0-17.2) of cases. Cystotomy complicated 13.02% (95% CI, 9.2-17.3) of surgical operations. Intentional cystotomy was required in 5.58% (95% CI, 2.7-9.3) of cases while damage to the bladder occurred in 7.40% (95% CI, 4.3-11.2) of cases. Urologic complications occurred in 19.36% (95% CI, 16.3-22.7) of cases undergoing hysterectomy and 12.22% (95% CI, 7.5-17.8) of those having conservative treatment. In the sub-group analyses, urologic complications occurred in 9.42% (95% CI, 5.4-14.4) of women with placenta accreta-increta and 38.52% (95% CI, 21.6-57.0) of those described as placenta percreta and were mainly represented by cystotomy (5.53% (95% CI, 0.6-15.1) in women with placenta accreta increta

and 21.97% (95% CI, 15.4-45.5) in the placenta percreta subgroup). Urologic complications occurred in 15.44% (95% CI, 8.1-24.6) during planned procedures and in 24.61% (95% CI, 13.0-38.5) during emergency intervention. The incidence of urologic complications was similar to that reported in the primary analysis in studies reporting >10 cases per year.

**Conclusions:** Patients undergoing surgery for PAS disorders are at high-risk of urologic complications, mainly cystotomy. The incidence of these complications is higher in patients described as having a placenta percreta at birth and in case of emergency surgical intervention. The high heterogeneity highlights the need to use standardized protocols for the diagnosis of PAS to identify prenatal imaging signs associated with a risk of urologic morbidity at delivery.

## INTRODUCTION

Placenta accreta spectrum (PAS) disorders encompass an heterogeneous group of conditions which occurs when the gestational sac implants and the definitive placenta develops within a uterine scar area<sup>1,2</sup>. The incidence of PAS disorders has significantly increased over the past decade, mainly because of the increasing cesarean delivery (CD) rates, and is now estimated to complicate approximately 1 in 1000 deliveries<sup>1,2</sup>. The prevalence of PAS is directly linked to the number of prior CD and thus countries with high CD and fertility rates have the highest rate of PAS and associated maternal morbidity and mortality<sup>3-5</sup>.

Patients with PAS at birth are at high risk of hemorrhagic complications, in particular when PAS is not suspected before birth<sup>6,7</sup>. Over 90 % of patients with PAS at birth also present with a low-lying/placenta previa, extended remodeling of the lower uterine segment and increased vascularization of the placental bladder interface and surrounding pelvic tissue, further increasing the risks of complications during surgical delivery<sup>7-9</sup>. Distortion of the normal pelvic anatomy with the presence of large bladder-uterovaginal anastomoses, bulging of the part of the placenta into the bladder or laterally into the parametrium and thick pelvic adhesions increase the risks of ureteral and bladder unintentional damage<sup>10-12</sup>. The incidence of urologic complications is also increased when intentional cystotomy is required due of a lack of a cleavage between the anterior wall of the uterus and the posterior bladder.

The incidence of urologic complication in pregnancies complicated by PAS disorders has not been evaluated. Small sample size of published cohort studies, absence of stratification for the type of surgery, and major variations in surgical protocols between centres limits the estimation of the risk of urologic complication associated with the surgical management of PAS. The objective of this systematic review and meta-analysis is to review the available

literature to identify the incidence of urologic complications and impact of the type of surgical procedure and placement of stents in patients with PAS disorders.

Accepted Article

## METHODS

### Protocol, eligibility criteria, information sources and search

This review was performed according to a priori designed protocol recommended for systematic reviews and meta-analysis<sup>13,14</sup>. Medline, Embase, Cinahl and Clinicaltrials.gov databases were searched electronically up to 1<sup>st</sup> of November 2022 (Table S1). The search protocol was designed *a priori* and registered on PROSPERO (CRD42022383373). The overall search strategy was inclusive of MeSH headings for “placenta accreta, placenta increta, placenta percreta, abnormally invasive placenta and morbidly adherent placenta” which were combined with terms including “urologic complications, bladder damage and ureteral damage”. Title, abstracts and full-text were independently assessed by the authors for content, data extraction and analysis. Additional relevant studies were identified from reference lists of reviews and editorials and by hand-searching key journals and websites. All search results were combined in a reference database. Duplicates were removed by hand. The search was limited to articles published in English. Prisma guidelines were followed<sup>15</sup>.

### Study selection, data collection and data items

The inclusion criteria were patients undergoing surgery for PAS.

The primary outcome was the overall incidence of urologic complications in women undergoing surgery for PAS.

The secondary outcomes included:

- Cystotomy (overall)
- Intentional cystotomy
- Unintentional cystotomy
- Ureteral damage

- Ureteral or bladder fistula

All these outcomes were explored in the overall population of women undergoing surgery for PAS. Sub-group analyses were performed according to the type of surgical procedure (hysterectomy or conservative techniques), planned or emergency intervention, grade of PAS and the number of cases performed by the authors per year ( $\geq 10$  per year)

### **Study selection and risk of bias**

Only full-text articles were considered eligible for inclusion; case reports, conference abstracts, and case series with  $< 10$  cases were also excluded to avoid publication bias.

Two independent investigators (AL, ST) selected studies in two stages. The abstracts of all potentially relevant papers were individually examined for suitability. Papers were only ruled out at this stage if they obviously did not meet the inclusion criteria. The remainder were obtained in full text and were independently assessed for content, data extraction and analysis. Disagreements between the two original reviewers were resolved by discussion with the third investigator (FDA). Full text copies of those papers were obtained. Study characteristics and surgical outcomes were extracted using a predesigned data extraction protocol. If more than one study was published on the same cohort with identical endpoints, the report containing the most comprehensive information on the population was included to avoid overlapping populations.

Two independent reviewers (AL, ST) undertook the quality assessment with difference agreed by consensus. Quality assessment of the included studies was performed using the Newcastle-Ottawa Scale (NOS) for case-control and cohort studies. According to NOS, each study is judged on three broad perspectives: the selection of the study groups; the comparability of the groups; and the ascertainment of the outcome of interest. Assessment of the selection of



a study includes the evaluation of the representativeness of the exposed cohort, selection of the non-exposed cohort, ascertainment of exposure and the demonstration that the outcome of interest was not present at the start of study. Assessment of the comparability of the study includes the evaluation of the comparability of cohorts based on the design or analysis. Finally, the ascertainment of the outcome of interest includes the evaluation of the type of the assessment of the outcome of interest, length and adequacy of follow-up. According to NOS a study can be awarded a maximum of one star for each numbered item within the Selection and Outcome categories. A maximum of two stars can be given for Comparability<sup>16</sup>.

### **Statistical analysis**

Analyses were conducted using the StatsDirect software version 2.7.9 (StatsDirect, Ltd, Altrincham, Cheshire, UK). Random effects model of proportions were used to analyse the data. Tests for funnel plot asymmetry were not used when the total number of publications included for each outcome was less than ten. In this case, the power of the tests is too low to distinguish chance from real asymmetry<sup>17</sup>.

Statistical heterogeneity was assessed with the Cochran's Q-test and the  $I^2$  statistic (the proportion of variation in study estimates because of heterogeneity rather than sampling error). A value of 0% indicates no observed heterogeneity, whereas  $I^2$  values of  $\geq 50\%$  indicate a substantial level of heterogeneity. A fixed effect model was used when  $I^2$  values were  $<50\%$ ; conversely a random effect model was used when  $I^2$  values were  $\geq 50\%$ <sup>17</sup>.

## RESULTS

The initial search provided with 847 articles, 749 were excluded as the reported outcomes were not relevant, leaving 97 studies which were obtained for full text review. An additional 35 articles were excluded after full review leaving 62 articles for the systematic review<sup>18-79</sup> (Table 1, Figure 1, Table S2).

The results of the quality assessment of the included studies using NOS scale tool are presented in Table 2. The included studies showed an overall good score regarding the selection and comparability of the study groups, and for ascertainment of the outcome of interest. Their major limitations were the retrospective design and lack of stratification of the analysis according to type of intervention, prenatal diagnosis, and surgeons' experience.

### Synthesis of results

The primary analysis included 11618 patients undergoing surgery for PAS. Urologic complications was found in 15.29% (95% CI, 13.0-17.2) of cases. Most of the studies did not specifically report the type of urologic morbidity. Cystotomy was reported 13.02% (95% CI, 9.2-17.3) of surgical operations. Intentional cystotomy was performed in 5.58% (95% CI, 2.7-9.3) of cases whereas unintentional damage to the bladder was found in 7.40% (95% CI, 4.3-11.2) of cases. 2.45% (95% CI, 1.4-3.9) of patients had ureteral damage and 1.44% (95% CI, 0.9-2.2) ureteral or vesicovaginal fistulas (Table 3).

In the subgroup of patients undergoing hysterectomy for PAS at birth, urologic complications were reported in 19.36% (95% CI, 16.3-22.7) of the cases, mainly due to cystotomy (17.05% (95% CI, 14.1-20.3)). Intentional cystotomy was performed in 8.69% (95% CI, 4.8-13.6) of cases whereas unintentional opening of the bladder occurred in 9.27% (95% CI, 5.2-14.4) of surgical procedure. Ureteral damage and ureteral or vesicovaginal fistulas were

reported in 1.80% (95% CI, 1.2-2.5) and 1.81% (95% CI, 1.0-2.9) of cases, respectively (Table 3).

In the subgroup of patients who had conservative management (partial myometrial resection of the PAS area or the placenta left in situ), urologic complications were reported in 12.22% (95% CI, 7.5-17.8) of cases and cystotomy in 9.58% (95% CI, 5.7-14.4). Intentional cystotomy was performed in 2.86% (95% CI, 0.7-6.5), while whereas unintentional opening of the bladder occurred in 7.28% (95% CI, 2.2-14.9) of cases. Ureteral damage and ureteral or vesicovaginal fistulas were reported in 2.05% (95% CI, 0.6-4.3) and in 0.42% (95% CI, 0.01-1.1) of the included cases.

### **Stratification analyses: PAS grade, emergency intervention, ureteral stents and number of cases per year**

#### *PAS grade*

Urologic complications occurred in 9.42% (95% CI, 5.4-14.4) of patients with placenta accreta-increta compared to 38.52% (95% CI, 21.6-57.0) for those described as placenta percreta, mainly cystotomy (5.53% (95% CI, 0.6-15.1) in placenta accreta/increta and 21.97% (95% CI, 15.4-45.5) in placenta percreta) (Table 4). Intentional cystotomy was performed in 6.50% (95% CI, 0.2-20.9) of patients with placenta accreta/increta and 11.47% (95% CI, 2.0-27.2) for those with placenta percreta. Unintentional cystotomy was found in 5.08% (95% CI, 0.03-11.8) and 4.47% (95% CI, 1.7-8.4) of the cases of placenta accreta/increta and placenta percreta, respectively. Ureteral injury was reported in 1.33% (95% CI, 0.07-4.11) in placenta accreta/increta and 3.56% (95% CI, 0.9-7.8) in placenta percreta. The occurrence of urologic complications was higher in patients undergoing hysterectomy compared to uterine preserving approaches (Table 4).

### *Type of intervention*

Urologic complications were reported in 15.44% (95% CI, 8.1-24.6) of patients undergoing planned compared to 24.61% (95% CI, 13.0-38.5) of those with an emergency intervention (Table 5).

### *Annual number of surgical procedure*

The incidence of urologic complications was similar to that reported in the primary analysis when considering only studies with >12 cases per year (Table S3).

## **DISCUSSION**

### **Main findings**

Our systematic review provides a comprehensive evaluation of the incidence of urologic complications associated with surgery for PAS. Patients with placenta percreta and those requiring an emergent delivery had the highest incidence of urologic complications, mainly cystotomy.

### **Strengths and limitations**

The main strengths of the present study include a thorough literature search, large sample size, multitude of outcomes explored and stratification of the analysis according to the type of intervention and severity of PAS disorders at birth, while its main limitations rely in the retrospective non-randomized design of the included studies, dissimilarity in the included populations and heterogeneity in outcome assessment. In particular, we could not stratify all the secondary analyses according to the type of surgical procedure, gestational age at surgery or use of interventional radiology techniques. Assessment of the potential publication bias may also be a limitation due to the nature of the outcome evaluated (outcome rates, with the left-side limited to a value of zero).

### **Clinical and research implications**

The rate of CD has been increasing annually; however, the overall rate of lower urinary tract injury has not changed and has remained at 0.3 % of all CDs<sup>80</sup>. In hysterectomy for benign indications, urologic complications have been reported in about 1% of cases including ureteral injuries in 1%, bladder injuries in 0.7% and genitourinary fistulas in 0.3% of cases<sup>81</sup>. Urologic complications in the context of radical hysterectomy for oncological conditions are higher with 1.48 % of patients reported with these complications<sup>82</sup>. By contrast, surgical procedures in

cases of PAS are usually complex, associated with a high risk of massive obstetric bleeding and of urological complications, such as injuries of the ureter and bladder<sup>29</sup>. The risk of major surgical complications is also increased in cases where there is high vascularity across myometrial placental bladder interface, extensive bladder adhesions, large area of dehiscent myometrium including most of the utero-bladder interface and placental bulging<sup>83</sup>. In particular, when the latter is protruding laterally into the parametria there is often increased broad ligament vascularity which when combined with thick adhesions between the herniated sac containing part of the placenta can make the surgical dissection difficult and increasing the risk of major intra-operative bleeding. Placental bulging can also cover the junction between the lower uterine segment and the cervix increasing the risk of ureteral injury and/or of the bladder trigone if a hysterectomy is required.

Placenta percreta represent the most severe clinical phenotype of PAS and occurs in case of an extended remodelling of the lower uterine segment with part of the basal plate of an anterior low-lying/placenta previa visible through the scar area <sup>84-87</sup>. A recent systematic review<sup>88</sup> of case reports described as placenta percreta in the international literature, which included histopathologic findings and gross images found no histologic evidence supporting the existence of a condition where the villous tissue penetrates the entire uterine wall including the serosa and beyond. Thus, it is likely that many of the cases described as percreta in the present study may not have been associated with accreta placentation but the consequence of LUS remodelling after multiple CDs. However, these cases are surgically complex that part of the placenta is accreta or not<sup>88</sup>.

Accurate risk stratification is also crucial for an objective presurgical planning<sup>89</sup>. Imaging features such as myometrial thinning and placental bulging are well established signs of extensive uterine remodeling on both ultrasound<sup>90</sup> and magnetic resonance imaging (MRI)<sup>91</sup>

and should alert the surgical team about anatomical changes that can impact the risk of intraoperative complications<sup>92</sup>. More specific ultrasound signs associated with a high probability of PAS at birth<sup>92</sup> such as increased sub-placental vascularity and placental lacunae are well established but there are limited data on the use of these imaging techniques in identifying patients at high risk of surgical morbidity. Several ultrasound and MRI staging systems of PAS have been reported in the published literature, but they still require validation in larger cohort<sup>93-100</sup>. More importantly, these studies have used composite scores of adverse surgical outcomes mainly based upon parameters which cannot directly reflect the surgical complexity, such as the need of blood transfusion of blood product, and are largely influenced by other cofactors, such as surgeon's experience or type of intervention.

Optimal surgical management of PAS disorders is difficult to defined yet as there are no randomized trials comparing the different surgical strategies for patients at high risk of PAS<sup>102,103</sup>. Primary hysterectomy is currently the most common surgical procedure for PAS management worldwide. More recently conservative techniques have been proposed, such as the one step surgery or the Triple P procedures<sup>93</sup>, but these also require a surgical expertise beyond that require for a standard CD. There is also high heterogeneity between studies regarding the different surgical steps (i.e. bladder dissection), surgical expertise and confirmation of the diagnosis of PAS and extension of the accreta lesion limiting the interpretation of the results<sup>94</sup>. Alternatively, management of PAS can imply leaving the placenta in the uterus and waiting for progressive delivery of the placenta which can occur months after the CD<sup>24</sup>. The findings highlight the need for a standardized reporting protocol for the different type of urologic complications according to the PAS grade, type of surgery and surgical technique used.

However, irrespective of the type of management adopted, surgery for PAS implies the need of an extensive knowledge of the pelvic anatomy and vascularity. Abnormal pelvic angioarchitecture which co-exist with PAS can lead to a distortion of the normal relationship between the uterus and the ureters, thus making their damage more likely. Furthermore, massive blood loss which can occur in the context of PAS may require an expedite execution of the caesarean hysterectomy to avoid patient's death. In this scenario, it is collective authors' opinion that women with PAS should be managed in centers with high expertise in surgical management of these complications, with the potential capacity to involve surgeons with high expertise in pelvic dissection, including gynecologic oncologists and urologists.

### **Conclusions**

Patients undergoing surgery for PAS disorders have a high risk of urological complications, irrespective of the type of intervention, which occurred more commonly in those undergoing emergency surgery and in cases presenting with major uterine remodeling. The data of this systematic review support the need for a tailored management and the need for multidisciplinary management including a urologist. The high heterogeneity between the studies analyzed in the systematic review highlight the need for a standardized protocols that include detailed description of the finding at birth to allow for better prenatal identification of cases at high risk of urologic morbidity. Multicentric prospective studies are needed to confirm to develop management strategies to reduce the burden of urologic complications in patients with PAS



## REFERENCES

1. Jauniaux E, Grønbeck L, Bunce C, Langhoff-Roos J, Collins SL. Epidemiology of placenta previa accreta: a systematic review and meta-analysis. *BMJ Open* 2019; **9**: e031193
2. Jauniaux E, Chantraine F, Silver RM, Langhoff-Roos J; FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO consensus guidelines on placenta accreta spectrum disorders: Epidemiology. *Int J Gynaecol Obstet* 2018; **140**: 265-273.
3. Iacovelli A, Liberati M, Khalil A, Timor-Trisch I, Leombroni M, Buca D, Milani M, Flacco ME, Manzoli L, Fanfani F, Cali G, Familiari A, Scambia G, D'Antonio F. Risk factors for abnormally invasive placenta: a systematic review and meta-analysis. *J Matern Fetal Neonatal Med* 2020; **33**: 471-481.
4. Tinari S, Buca D, Cali G, Timor-Tritsch I, Palacios-Jaraquemada J, Rizzo G, Lucidi A, Di Mascio D, Liberati M, D'Antonio F. Risk factors, histopathology and diagnostic accuracy in posterior placenta accreta spectrum disorders: systematic review and meta-analysis. *Ultrasound Obstet Gynecol* 2021; **57**: 903-909.
5. Cali G, Timor-Tritsch IE, Palacios-Jaraquemada J, Monteaugudo A, Buca D, Forlani F, Familiari A, Scambia G, Acharya G, D'Antonio F. Outcome of Cesarean scar pregnancy managed expectantly: systematic review and meta-analysis. *Ultrasound Obstet Gynecol* 2018; **51**: 169-175.
6. Buca D, Liberati M, Cali G, Forlani F, Caisutti C, Flacco ME, Manzoli L, Familiari A, Scambia G, D'Antonio F. Influence of prenatal diagnosis of abnormally invasive placenta on maternal outcome: systematic review and meta-analysis. *Ultrasound Obstet Gynecol* 2018; **52**: 304-309.
7. Hussein AM, Fox K, Bhide A, Elbarmelgy RA, Elbarmelgy RM, Thabet MM, Jauniaux E. The impact of preoperative ultrasound and intraoperative findings on surgical outcomes in patients at high risk of placenta accreta spectrum. *BJOG* 2023; **130**: 42-50.
8. Hussein AM, Elbarmelgy RA, Elbarmelgy RM, Thabet MM, Jauniaux E. Prospective evaluation of impact of post-Cesarean section uterine scarring in perinatal diagnosis of placenta accreta spectrum disorder. *Ultrasound Obstet Gynecol* 2022; **59**: 474-482.
9. Cali G, D'Antonio F, Forlani F, Timor-Tritsch IE, Palacios-Jaraquemada JM. Ultrasound detection of bladder-uterovaginal anastomoses in morbidly adherent placenta. *Fetal Diagn Ther* 2017; **41**: 239-240.

10. D'Antonio F, Palacios-Jaraquemada J, Lim PS, Forlani F, Lanzone A, Timor-Tritsch I, Cali G. Counseling in fetal medicine: evidence-based answers to clinical questions on morbidly adherent placenta. *Ultrasound Obstet Gynecol* 2016; **48**: 544.
11. Jauniaux E, Bhide A. Prenatal ultrasound diagnosis and outcome of placenta previa accreta after cesarean delivery: a systematic review and meta-analysis. *Am J Obstet Gynecol* 2017; **217**: 27-36.
12. Palacios-Jaraquemada JM, D'Antonio F, Buca D, Fiorillo A, Larraza P. Systematic review on near miss cases of placenta accreta spectrum disorders: correlation with invasion topography, prenatal imaging, and surgical outcome. *J Matern Fetal Neonatal Med* 2020; **33**: 3377-3384.
13. NHS Centre for Reviews and Dissemination. Systematic reviews: CRD's guidance for undertaking reviews in health care. University of York: York (UK), 2009. Available at: [https://www.york.ac.uk/media/crd/Systematic\\_Reviews.pdf](https://www.york.ac.uk/media/crd/Systematic_Reviews.pdf). Retrieved December 3, 2016.
14. Henderson LK, Craig JC, Willis NS, Tovey D, Webster AC. How to write a Cochrane systematic review. *Nephrology (Carlton)* 2010; **15** :617-624.
15. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. *JAMA* 2000; **283**: 2008–2012.
16. Newcastle-Ottawa Scale for assessing the quality of nonrandomised studies in meta-analyses. Available at: [http://www.ohri.ca/programs/clinical\\_epidemiology/oxford.asp](http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp)
17. Hunter JP, Saratzis A, Sutton AJ, Boucher RH, Sayers RD, Bown MJ. In meta-analyses of proportion studies, funnel plots were found to be an inaccurate method of assessing publication bias. *J Clin Epidemiol* 2014; **67**: 897–903.
18. Dawood AS, Dawood AS, Shazly SA, Assar TM, Soliman AS. A randomized controlled study comparing two uterine sparing techniques in conservative management of placenta accreta spectrum. *Int J Gynaecol Obstet* 2022. DOI: 10.1002/ijgo.14419. Epub ahead of print.
19. Kuznetsova N, Bushtyreva I, Barinova V, Shmakova K. Bladder filling technique to prevent complications of the urinary system during placenta accrete surgery. *J MaternFetal Neonatal Med* 2022; **35**: 607-609.
20. Munoz JL, Blankenship LM, Ramsey PS, McCann GA. Importance of the gynecologic oncologist in management of cesarean hysterectomy for Placenta Accreta Spectrum (PAS). *Gynecol Oncol* 2022; **166**: 460-464.

21. Overton E, Booker WA, Mourad M, Moroz L, Nhan Chang CL, Breslin N, Syeda S, Laifer-Narin S, Cimic A, Chung DE, Weiner DM, Smiley R, Sheikh M, Mobley DG, Wright JD, Gockley A, Melamed A, St Clair C, Hou J, D'Alton M, Khoury Collado F. Prophylactic endovascular internal iliac balloon placement during cesarean hysterectomy for placenta accreta spectrum. *Am J Obstet Gynecol MFM* 2022; **4**: 100657.
22. Pavón-Gomez N, López R, Altamirano L, Cabrera SB, Rosales GP, Chamorro S, González K, Morales A, Maya J, Sinisterra S, Nieto-Calvache AJ. Relationship between the prenatal diagnosis of placenta accreta spectrum and lower use of blood components. *Rev Bras Ginecol Obstet* 2022; **44**: 1090-1093.
23. Scaglione MA, Allshouse AA, Canfield DR, Mclaughlin HD, Bruno AM, Hammad IA, Branch DW, Maurer KA, Dood RL, Debbink MP, Silver RM, Einerson BD. Prophylactic ureteral stent placement and urinary injury during hysterectomy for placenta accreta spectrum. *Obstet Gynecol* 2022; **140**: 806-811.
24. Sentilhes L, Seco A, Azria E, Beucher G, Bonnet MP, Branger B, Carbillon L, Chiesa C, Crenn-Hebert C, Dreyfus M, Dupont C, Fresson J, Huissoud C, Langer B, Morel O, Patrier S, Perrotin F, Raynal P, Rozenberg P, Rudigoz RC, Vendittelli F, Winer N, Deneux-Tharoux C, Kayem G; PACCRETA Study Group. Conservative management or cesarean hysterectomy for placenta accreta spectrum: the PACCRETA prospective study. *Am J Obstet Gynecol* 2022; **226**: 839.
25. Smith CG, Cottrill HM, Barton JR. Reloadable Stapler Use during Peripartum Hysterectomy for Placenta Accreta Spectrum: A Novel Surgical Technique and Case Series. *Am J Perinatol* 2022; **39**: 265-271.
26. Taskeen R, Durri Iram R, Khan S, Bashir H, Baber R. Reducing Mortality and Morbidity in Morbidly Adherent Placenta. *PJMH* SVol. 16, No.02, FEB 2022
27. Xin S, Wan H, Zeng X, Fu Y, Wang Z, Lai H, Xiong Y, Zheng J, Liu L. Early warning model of placenta accreta spectrum disorders complicated with cervical implantation: a single-center retrospective study. *J Healthc Eng* 2022. DOI: 10.1155/2022/8128689.
28. Bakacak Z, Bakacak M, Güzin K, Yazar FM, Yaylalı A, Uzkar A. An examination by year of cases applied with caesarean hysterectomy because of placenta percreta in a tertiary centre: a retrospective cohort study. *Ginekol Pol* 2021; **92**: 284-288.
29. Erfani H, Salmanian B, Fox KA, Coburn M, Meshinchiasl N, Shamshirsaz AA, Kopkin R, Gogia S, Patel K, Jackson J, Cadena M, Aalipour S, Sukumar S, Nassr AA, Espinoza J, Clark SL, Belfort MA, Shamshirsaz AA. Urologic morbidity associated with placenta

accreta spectrum surgeries: single-center experience with a multidisciplinary team. *Am J Obstet Gynecol* 2022; **226**: 245.

30. Matsuzaki S, Mandelbaum RS, Sangara RN, McCarthy LE, Vestal NL, Klar M, Matsushima K, Amaya R, Ouzounian JG, Matsuo K. Trends, characteristics, and outcomes of placenta accreta spectrum: a national study in the United States. *Am J ObstetGynecol*2021; **225**: 534.
31. Morlando M, Schwickert A, Stefanovic V, Gziri MM, Pateisky P, Chalubinski KM, Nonnenmacher A, Morel O, Braun T, Bertholdt C, Van Beekhuizen HJ, Collins SL; International Society for Placenta Accreta Spectrum (IS-PAS). Maternal and neonatal outcomes in planned versus emergency cesarean delivery for placenta accreta spectrum: A multinational database study. *Acta Obstet Gynecol Scand* 2021; **100**: 41-49.
32. Parveen F, Aijaz S, Memon SA, Memon FN, Enayat R. Maternal Outcomes in the Management of Morbidly Adherent Placenta: Multidisciplinary Team vs. Standard Care at a Tertiary Care Hospital. *Pakistan Journal of Medical Research*. 2021; **60**: 2-7.
33. SoleymaniMajd H, Collins SL, Addley S, Weeks E, Chakravarti S, Halder S, Alazzam M. The modified radical peripartum cesarean hysterectomy (Soleymani-Alazzam-Collins technique): a systematic, safe procedure for the management of severe placenta accreta spectrum. *Am J ObstetGynecol* 2021; **225**: 175.
34. Uddén A, Carlsson Y, Karlsson O, Peeker R, Svanvik T. Placenta accreta spectrum-A single-center retrospective observational cohort study of multidisciplinary management over time. *Int J GynaecolObstet* 2022; **159**: 270-278.
35. van Beekhuizen HJ, Stefanovic V, Schwickert A, Henrich W, Fox KA, MHallemGziri M, Sentilhes L, Gronbeck L, Chantraine F, Morel O, Bertholdt C, Braun T, Rijken MJ, Duvekot JJ; International Society of Placenta Accreta Spectrum (IS-PAS) group. A multicenter observational survey of management strategies in 442 pregnancies with suspected placenta accreta spectrum. *Acta ObstetGynecolScand*2021; **100**: 12-20.
36. Chahal HS, Juneja SK, Kaur S, Kochar B, Sharma S, Makkar V. Pregnancy-related acute kidney injury and urological comorbidities in morbidly adherent placenta: A potential challenge to AKI-0by25. *Saudi J Kidney Dis Transpl* 2020; **31**: 368-379.
37. Dall'Asta A, Cali G, Forlani F, Paramasivam G, Girardelli S, Yazbek J, D'Antonio F, Bhide A, Lees CC. Evaluation of perioperative complications using a newly described staging system for placenta accreta spectrum. *Eur J ObstetGynecol Reprod Biol* 2020; **250**: 54-60.

38. Nsiar N, Ghaffar S, Jokhio F. Morbid adherent Placenta: morbidity and mortality report from a developing country. *J Liaquat Uni Med Health Sci* 2020; **19**: 82-86.
39. Saha PK, Bagga R, Kalra JK, Arora A, Singla R, Suri V, Jain K, Kumar P, Gupta N, Jain A, Singh T, Mavuduru RS. An alternate surgical approach to reduce hemorrhage and complications during cesarean hysterectomy for adherent placenta. *Eur J ObstetGynecolReprod Biol.* 2018; **228**: 215-220.
40. Celik S, Celik H, SoyerCaliskan C, Tosun M, Hatirnaz S. Bladder filling before accreta surgery is a very effective method for preventing bladder injury: a retrospective cohort study. *J MaternFetal Neonatal Med.* 2021; **34**: 2206-2211.
41. Crocetto F, Esposito R, Saccone G, Della Corte L, Sarno L, Morlando M, Maruotti GM, Migliorini S, D'Alessandro P, Arduino B, Raffone A, Travaglino A, Improda FP, Bifulco G, Martinelli P, Imbimbo C, Zullo F. Use of routine ureteralstents in cesareanhysterectomy for placenta accreta. *J Matern Fetal Neonatal Med* 2021; **34**: 386-389.
42. Dawood AS, Elgergawy AE, Elhalwagy AE. Evaluation of three-step procedure (Shehata's technique) as a conservative management for placenta accreta at a tertiary care hospital in Egypt. *J Gynecol Obstet Hum Reprod* 2019; **48**: 201-205.
43. Nieto-Calvache AJ, López-Girón MC, Messa-Bryon A, Ceballos-Posada ML, Duque-Galán M, Ríos-Posada JG, Plazas-Córdoba LA, Chancy-Castaño MM. Urinary tract injuries during treatment of patients with morbidly adherent placenta. *J Matern Fetal Neonatal Med* 2021; **34**: 3140-3146.
44. Sak S, Barut M, Incebiyik A, Uyanikoglu H, Hilali N, Sak M. Management of peripartum hysterectomies performed on patients with placenta percreta in a tertiary central hospital. *J Matern Fetal Neonatal Med* 2019; **32**: 883-888.
45. Zuckerwise LC, Craig AM, Newton JM, Zhao S, Bennett KA, Crispens MA. Outcomes following a clinical algorithm allowing for delayed hysterectomy in the management of severe placenta accreta spectrum. *Am J Obstet Gynecol* 2020; **222**: 179.
46. Marcellin L, Delorme P, Bonnet MP, Grange G, Kayem G, Tsatsaris V, Goffinet F. Placenta percreta is associated with more frequent severe maternal morbidity than placenta accreta. *Am J Obstet Gynecol* 2018; **219**: 193.
47. Meller CH, Garcia-Monaco RD, Izbizky G, Lamm M, Jaunarena J, Peralta O, Otaño L. Non-conservative management of placenta accreta spectrum in the hybrid operating room: a retrospective cohort study. *Cardiovasc Intervent Radiol* 2019; **42**: 365-370.



48. Özcan HÇ, Balat Ö, Uğur MG, Sucu S, Tepe NB, Kazaz TG. Use of bladder filling to prevent urinary system complications in the management of placenta percreta: a randomized prospective study. *Geburtshilfe Frauenheilkd* 2018; **78**: 173-178.
49. Shmakov RG, Vinititskiy AA, Chuprinin VD, Yarotskaya EL, Sukhikh GT. Alternative approaches to surgical hemostasis in patients with morbidly adherent placenta undergoing fertility-sparing surgery. *J Matern Fetal Neonatal Med* 2019; **32**: 2042-2048.
50. Thabet M, Abdelhafez MS, Fyala EA. Intrauterine inflated Foley's catheter balloon in the management of abnormally invasive placenta previa: a case-control study. *J ObstetGynaecol India* 2018; **68**: 185-191.
51. Zhao X, Tao Y, Du Y, Zhao L, Liu C, Zhou Y, Wei P. The application of uterine wall local resection and reconstruction to preserve the uterus for the management of morbidly adherent placenta: Case series. *Taiwan J ObstetGynecol* 2018; **57**: 276-282.
52. Alanwar A, Al-Sayed HM, Ibrahim AM, Elkotb AM, Abdelshafy A, Abdelhadi R, Abbas AM, Abdelmenam HS, Fares T, Nossair W, Abdallah AA, Sabaa H, Nawara M. Urinary tract injuries during cesarean section in patients with morbid placental adherence: retrospective cohort study. *J Matern Fetal Neonatal Med* 2019; **32**: 1461-1467.
53. Lee PS, Kempner S, Miller M, Dominguez J, Grotegut C, Ehrisman J, Previs R, Havrilesky LJ, Broadwater G, Ellestad SC, Secord AA. Multidisciplinary approach to manage antenatally suspected placenta percreta: updated algorithm and patient outcomes. *Gynecol Oncol Res Pract* 2017; **4**: 11.
54. Pala Ş, Atilgan R, Başpınar M, Kavak EÇ, Yavuzkır Ş, Akyol A, Kavak B. Comparison of results of Bakri balloon tamponade and caesarean hysterectomy in management of placenta accreta and increta: a retrospective study. *J Obstet Gynaecol* 2018; **38**: 194-199.
55. Chaudhari HK, Shah PK, D'Souza N. Morbidly Adherent Placenta: Its Management and Maternal and Perinatal Outcome. *J Obstet Gynaecol India* 2017; **67**: 42-47.
56. Karaman E, Kulusarı A, Çetin O, Çim N, Alkış İ, Yıldızhan R, Şahin HG, Gül A. Local resection may be a strong alternative to cesarean hysterectomy in conservative surgical management of placenta percreta: experiences from a tertiary hospital. *J Matern Fetal Neonatal Med* 2017; **30**: 947-952
57. Camuzcuoglu A, Vural M, Hilali NG, Incebiyik A, Yuce HH, Kucuk A, Camuzcuoglu H. Surgical management of 58 patients with placenta praevia percreta. *Wien Klin Wochenschr* 2016; **128**: 360-366.

58. Fitzpatrick KE, Sellers S, Spark P, Kurinczuk JJ, Brocklehurst P, Knight M. The management and outcomes of placenta accreta, increta, and percreta in the UK: a population-based descriptive study. *BJOG* 2014; **121**: 62-70.
59. Norris BL, Everaerts W, Posma E, Murphy DG, Umstad MP, Costello AJ, Wrede CD, Kearsley J. The urologist's role in multidisciplinary management of placenta percreta. *BJU Int* 2016; **117**: 961-965.
60. Shabana A, Fawzy M, Refaie W. Conservative management of placenta percreta: a stepwise approach. *Arch Gynecol Obstet* 2015; **291**: 993-998.
61. Thurn L, Lindqvist PG, Jakobsson M, Colmorn LB, Klungsoyr K, Bjarnadóttir RI, Tapper AM, Børdahl PE, Gottvall K, Petersen KB, Krebs L, Gissler M, Langhoff-Roos J, Källen K. Abnormally invasive placenta-prevalence, risk factors and antenatal suspicion: results from a large population-based pregnancy cohort study in the Nordic countries. *BJOG* 2016; **123**: 1348-55.
62. Shamshirsaz AA, Fox KA, Salmanian B, Diaz-Arrastia CR, Lee W, Baker BW, Ballas J, Chen Q, Van Veen TR, Javadian P, Sangi-Haghpeykar H, Zacharias N, Welty S, Cassady CI, Moaddab A, Popek EJ, Hui SK, Teruya J, Bandi V, Coburn M, Cunningham T, Martin SR, Belfort MA. Maternal morbidity in patients with morbidly adherent placenta treated with and without a standardized multidisciplinary approach. *Am J Obstet Gynecol* 2015; **212**: 218.e1-9.
63. Alchalabi H, Lataifeh I, Obeidat B, Zayed F, Khader YS, Obeidat N. Morbidly adherent placenta previa in current practice: prediction and maternal morbidity in a series of 23 women who underwent hysterectomy. *J Matern Fetal Neonatal Med* 2014; **27**: 1734-1737.
64. Asıcioglu O, Şahbaz A, Güngördük K, Yildirim G, Asıcioglu BB, Ülker V. Maternal and perinatal outcomes in women with placenta praevia and accreta in teaching hospitals in Western Turkey. *J Obstet Gynaecol* 2014; **34**: 462-466.
65. Brookfield KF, Goodnough LT, Lyell DJ, Butwick AJ. Perioperative and transfusion outcomes in women undergoing cesarean hysterectomy for abnormal placentation. *Transfusion* 2014; **54**: 1530-1536.
66. Cali G, Giambanco L, Puccio G, Forlani F. Morbidly adherent placenta: evaluation of ultrasound diagnostic criteria and differentiation of placenta accreta from percreta. *Ultrasound Obstet Gynecol* 2013; **41**: 406-412.
67. Woldu SL, Ordonez MA, Devine PC, Wright JD. Urologic considerations of placenta accreta: a contemporary tertiary care institutional experience. *Urol Int* 2014; **93**: 74-79.

68. Chantraine F, Braun T, Gonser M, Henrich W, Tutschek B. Prenatal diagnosis of abnormally invasive placenta reduces maternal peripartum hemorrhage and morbidity. *Acta Obstet Gynecol Scand* 2013; **92**: 439-444.
69. Chung MY, Cheng YK, Yu SC, Sahota DS, Leung TY. Nonremoval of an abnormally invasive placenta at cesarean section with postoperative uterine artery embolization. *Acta Obstet Gynecol Scand* 2013; **92**: 1250-1255.
70. Guleria K, Gupta B, Agarwal S, Suneja A, Vaid N, Jain S. Abnormally invasive placenta: changing trends in diagnosis and management. *Acta Obstet Gynecol Scand* 2013; **92**: 461-464.
71. Eller AG, Bennett MA, Sharshiner M, Masheter C, Soisson AP, Dodson M, Silver RM. Maternal morbidity in cases of placenta accreta managed by a multidisciplinary care team compared with standard obstetric care. *Obstet Gynecol* 2011; **117**: 331-337.
72. Meyer NP, Ward GH, Chandraharan E. Conservative approach to the management of morbidly adherent placentae. *Ceylon Med J* 2012; **57**: 36-39.
73. Tikkanen M, Paavonen J, Loukovaara M, Stefanovic V. Antenatal diagnosis of placenta accreta leads to reduced blood loss. *Acta Obstet Gynecol Scand* 2011; **90**: 1140-1146.
74. Sultana N, Mohyuddin S, Jabbar T. Management and maternal outcome in morbidly adherent placenta. *J Ayub Med Coll Abbottabad* 2011; **23**: 93-96.
75. Angstmann T, Gard G, Harrington T, Ward E, Thomson A, Giles W. Surgical management of placenta accreta: a cohort series and suggested approach. *Am J Obstet Gynecol* 2010; **202**: 38.
76. Hoffman MS, Karlinski RA, Mangar D, Whiteman VE, Zweibel BR, Lockhart JL, Camporesi EM. Morbidity associated with nonemergent hysterectomy for placenta accreta. *Am J Obstet Gynecol* 2010; **202**: 628.e1-5.
77. Sentilhes L, Ambroselli C, Kayem G, Provansal M, Fernandez H, Perrotin F, Winer N, Pierre F, Benachi A, Dreyfus M, Bauville E, Mahieu-Caputo D, Marpeau L, Descamps P, Goffinet F, Bretelle F. Maternal outcome after conservative treatment of placenta accreta. *Obstet Gynecol* 2010; **115**: 526-534.
78. Warshak CR, Ramos GA, Eskander R, Benirschke K, Saenz CC, Kelly TF, Moore TR, Resnik R. Effect of predelivery diagnosis in 99 consecutive cases of placenta accreta. *Obstet Gynecol* 2010; **115**: 65-69.
79. Wright JD, Devine P, Shah M, Gaddipati S, Lewin SN, Simpson LL, Bonanno C, Sun X, D'Alton ME, Herzog TJ. Morbidity and mortality of peripartum hysterectomy. *Obstet Gynecol* 2010; **115**: 1187-1193.



80. Oliphant SS, Bochenska K, Tolge ME, Catov JM, Zyczynski HM. Maternal lower urinary tract injury at the time of Cesarean delivery. *Int Urogynecol J* 2014; **25** : 1709-1714.
81. Dallas KB, Rogo-Gupta L, Elliott CS. Urologic Injury and Fistula After Hysterectomy for Benign Indications. *Obstet Gynecol* 2019; **134**: 241-249.
82. Hwang JH, Kim BW, Jeong H, Kim H. Comparison of urologic complications between laparoscopic radical hysterectomy and abdominal radical hysterectomy: A nationwide study from the National Health Insurance. *Gynecol Oncol* 2020; **158**: 117-122.
83. Jauniaux E, Fox K, Einerson A, Hecht JL, Silver RM. Perinatal assessment of Complex Cesarean Section Delivery: Beyond Placenta Accreta Spectrum. *Am J Obstet Gynecol* 2023.
84. Braun T, van Beekhuizen HJ, Morlando M, Morel O, Stefanovic V. International Society for Placenta Accreta Spectrum (IS-PAS). Developing a database for multicenter evaluation of placenta accreta spectrum. *Acta Obstet Gynecol Scand* 2021; **100**: 7-11.
85. Einerson BD, Comstock J, Silver RM, Branch DW, Woodward PJ, Kennedy A. Placenta accreta spectrum disorder: uterine dehiscence, not placental invasion. *Obstet Gynecol* 2020; **135**: 1104-1111.
86. Einerson BD, Kennedy A, Silver RM, Branch DW, Comstock J, Woodward PJ. Ultrasonography of the explanted uterus in placenta accreta spectrum: correlation with intraoperative findings and gross pathology. *Obstet Gynecol* 2023; **141**: 544-554.
87. Luke RK, Sharpe JW, Greene RR. Placenta accreta: The adherent or invasive placenta. *Am J Obstet Gynecol* 1966; **95**: 660–668.
88. Jauniaux E, Hecht JL, Elbarmelgy RA, Elbarmelgy RM, Thabet MM, Hussein AM. Searching for placenta percreta: a prospective cohort and systematic review of case reports. *Am J Obstet Gynecol* 2022; **226**: 837.
89. Hussein AM, Fox K, Bhide A, Elbarmelgy RA, Elbarmelgy RM, Thabet MM, Jauniaux E. The impact of preoperative ultrasound and intraoperative findings on surgical outcomes in patients at high risk of placenta accreta spectrum. *BJOG* 2023; **130**: 42-50.
90. Shinker SA, Coleman B, Timor-Tritsch IE, Bhide A, Bromley B, Cahill AG, Gandhi M, Hecht JL, Johnson KM, Levine D, Mastrobattista J, Philips J, Platt LD, Shamshirsaz AA, Shipp TD, Silver RM, Simpson LL, Copel JA, Abuhamad A; Society for Maternal-Fetal Medicine. Special Report of the Society for Maternal-Fetal Medicine Placenta Accreta Spectrum Ultrasound Marker Task Force: Consensus on definition of markers

and approach to the ultrasound examination in pregnancies at risk for placenta accreta spectrum. *Am J Obstet Gynecol* 2021; **224** : B2-B14.

91. Alamo L, Vial Y, Denys A, Andreisek G, Meuwly JY, Schmidt S. MRI findings of complications related to previous uterine scars. *Eur J Radiol Open* 2018; **5**: 6-15.
92. Jauniaux E, D'Antonio F, Bhide A, Prefumo F, Silver RM, Hussein AM, Shainker SA, Chantraine F, Alfirevic Z; Delphi consensus expert panel. Modified Delphi study of ultrasound signs associated with placenta accreta spectrum. *Ultrasound Obstet Gynecol* 2023. DOI: 10.1002/uog.26155.
93. Cali G, Forlani F, Lees C, Timor-Tritsch I, Palacios-Jaraquemada J, Dall'Asta A, Bhide A, Flacco ME, Manzoli L, Labate F, Perino A, Scambia G, D'Antonio F. Prenatal ultrasound staging system for placenta accreta spectrum disorders. *Ultrasound Obstet Gynecol* 2019; **53**: 752-760.
94. Di Mascio D, Cali G, D'antonio F. Updates on the management of placenta accreta spectrum. *Minerva Ginecol* 2019; **71**: 113-120.
95. Finazzo F, D'antonio F, Masselli G, Forlani F, Palacios-Jaraquemada J, Minneci G, Gambarini S, Timor-Tritsch I, Prefumo F, Buca D, Liberati M, Khalil A, Cali G. Interobserver agreement in MRI assessment of severity of placenta accreta spectrum disorders. *Ultrasound Obstet Gynecol* 2020; **55**:467-473.
96. Cali G, D'Antonio F. Radical surgery including the role of an interval hysterectomy. *Best Pract Res Clin Obstet Gynaecol* 2021; **72**: 75-83.
97. Palacios-Jaraquemada JM, D'Antonio F, Buca D, Fiorillo A, Larraza P. Systematic review on near miss cases of placenta accreta spectrum disorders: correlation with invasion topography, prenatal imaging, and surgical outcome. *J Matern Fetal Neonatal Med* 2020; **33**: 3377-3384.
98. Cali G, Forlani F, Timor-Trisch I, Palacios-Jaraquemada J, Foti F, Minneci G, Flacco ME, Manzoli L, Familiari A, Pagani G, Scambia G, D'Antonio F. Diagnostic accuracy of ultrasound in detecting the depth of invasion in women at risk of abnormally invasive placenta: A prospective longitudinal study. *Acta Obstet Gynecol Scand* 2018; **97**: 1219-1227.
99. Cali G, Timor-Trisch IE, Palacios-Jaraquemada J, Monteaugudo A, Forlani F, Minneci G, Foti F, Buca D, Familiari A, Scambia G, Liberati M, D'Antonio F. Changes in ultrasonography indicators of abnormally invasive placenta during pregnancy. *Int J Gynaecol Obstet* 2018; **140**: 319-325.

100. D'Antonio F, Timor-Tritsch IE, Palacios-Jaraquemada J, Monteagudo A, Buca D, Forlani F, Minneci G, Foti F, Manzoli L, Liberati M, Acharya G, Cali G. First-trimester detection of abnormally invasive placenta in high-risk women: systematic review and meta-analysis. *Ultrasound Obstet Gynecol* 2018; **51**: 176-183.
101. D'Antonio F, Palacios-Jaraquemada J, Lim PS, Forlani F, Lanzone A, Timor-Tritsch I, Cali G. Counseling in fetal medicine: evidence-based answers to clinical questions on morbidly adherent placenta. *Ultrasound Obstet Gynecol* 2016; **47**: 290-301.
102. Capannolo G, D'Amico A, Alameddine S, Di Girolamo R, Khalil A, Cali G, Trish IT, Coutinho CM, Herrera M, Liberati M, Lucidi A, Palacios-Jaraquemada J, Buca D, D'Antonio F. Placenta accreta spectrum disorders clinical practice guidelines: A systematic review. *J Obstet Gynaecol Res* 2023 Feb 16.
103. Cali G, D'Antonio F. Radical surgery including the role of an interval hysterectomy. *Best Pract Res Clin Obstet Gynaecol* 2021; **72**: 75-83.

## FIGURE LEGEND

**Figure 1.** Systematic review flowchart.

**Table 1.** General characteristics of the studies included in the systematic review.

Author	Year	Country	Study design	Period considered	Diagnosis of PAS	Stratification according to the type of intervention, interventional radiology techniques or use of ureteral stenting	Surgical technique	Cases (n)
Dawood <sup>18</sup>	2022	Egypt	RCT	2017-2020	Prenatal and at the time of CD	Not performed	Conservative surgery	200
Kuznetsova <sup>19</sup>	2022	Russia	Retrospective	2015-2018	Prenatal	Not performed	Conservative surgery	41
Munoz <sup>20</sup>	2022	United States	Retrospective	2011-2021	Prenatal	Not performed	Hysterectomy	122
Overton <sup>21</sup>	2022	United States	Retrospective	2018-2020	Prenatal and at the time of CD	Not performed	Hysterectomy	30
Pavon-Gomez <sup>22</sup>	2022	Colombia	Retrospective	2017-2021	Prenatal and at the time of CD	Not performed	Hysterectomy	114
Scaglione <sup>23</sup>	2022	United States	Retrospective	2001-2021	Prenatal and at the time of CD	Performed	Hysterectomy	236
Senthiles <sup>24</sup>	2022	France	Prospective	2013-2015	Prenatal	Not performed	Hysterectomy and conservative surgery	148
Smith <sup>25</sup>	2022	United States	Retrospective	2008-2020	Prenatal	Not performed	Hysterectomy	18
Taskeen <sup>26</sup>	2022	Kuwait	Retrospective	2018-2020	Prenatal and at the time of CD	Not performed	Hysterectomy	36
Xin <sup>27</sup>	2022	China	Retrospective	2016-2020	Prenatal and at the time of CD	Not performed	Hysterectomy and conservative surgery	166
Bakacak <sup>28</sup>	2021	Turkey	Retrospective	2005-2019	Prenatal and at the time of CD	Not performed	Hysterectomy	93
Erfani <sup>29</sup>	2021	United States	Retrospective	2011-2020	Prenatal and at the time of CD	Performed	Hysterectomy	292
Matsuzaki <sup>30</sup>	2021	United States	Retrospective	2015-2017	Prenatal and at the time of CD	Not performed	Hysterectomy and conservative surgery	8030
Morlando <sup>31</sup>	2021	Multinational	Retrospective	2014-2019	Prenatal and at the time of CD	Not performed	Hysterectomy and conservative surgery	356
Perveen <sup>32</sup>	2021	Pakistan	Retrospective	2018-2020	Prenatal	Not performed	Hysterectomy and conservative surgery	40
Soleymanimajd <sup>33</sup>	2021	United Kingdom	Retrospective	2011-2020	Prenatal and at the time of CD	Not performed	Hysterectomy	24

Udden <sup>34</sup>	2021	Sweden	Retrospective	2003-2020	Prenatal and at the time of CD	Not performed	Hysterectomy	33
van Beekhuizen <sup>35</sup>	2021	Multinational	Retrospective	2008-2019	Prenatal and at the time of CD	Not performed	Hysterectomy and conservative surgery	442
Chahal <sup>36</sup>	2020	India	Retrospective	2014-2017	Prenatal and at the time of CD	Performed	Hysterectomy and conservative surgery	64
Dall' Asta <sup>37</sup>	2020	Italy	Retrospective	2014-2018	Prenatally	Not performed	Hysterectomy	43
Nisar <sup>38</sup>	2020	Pakistan	Retrospective	2016	Prenatal and at the time of CD	Not performed	Not reported	68
Saha <sup>39</sup>	2020	India	Prospective	2015-2017	Prenatal	Not performed	Hysterectomy	12
Celik <sup>40</sup>	2019	Turkey	Retrospective	2009-2019	NS	Not performed	Hysterectomy	88
Crocetto <sup>41</sup>	2019	Italy	Retrospective	2010-2018	Prenatal	Not performed	Hysterectomy	44
Dawood <sup>42</sup>	2019	Egypt	Retrospective	2015-2017	Prenatal and at the time of CD	Not performed	Conservative surgery	91
Nieto-Calvache <sup>43</sup>	2019	Colombia	Retrospective	2011-2019	Prenatal and at the time of CD	Performed	Hysterectomy and conservative surgery	65
Sak <sup>44</sup>	2019	Turkey	Retrospective	2015-2016	Prenatal and at the time of CD	Not performed	Hysterectomy	37
Zuckerwise <sup>45</sup>	2019	United States	Retrospective	2012-2018	Prenatal	Not performed	Hysterectomy	49
Marcellin <sup>46</sup>	2018	France	Retrospective	2003-2017	Prenatal and at the time of CD	Not performed	Hysterectomy and conservative surgery	156
Meller <sup>47</sup>	2018	Argentina	Retrospective	2013-2017	Prenatal	Not performed	Hysterectomy	110
Ozcan <sup>48</sup>	2018	Turkey	Retrospective	2015-2017	Prenatal	Not performed	Hysterectomy	66
Shmakov <sup>49</sup>	2018	Russia	Retrospective	2015-2017	Prenatal	Not performed	Hysterectomy and conservative surgery	54
Thabet <sup>50</sup>	2018	Egypt	Retrospective	2013-2016	Prenatal	Not performed	Conservative surgery	78
Zhao <sup>51</sup>	2018	China	Retrospective	2013-2016	Prenatal	Not performed	Conservative management	62
Alanwar <sup>52</sup>	2017	Egypt	Retrospective	2014-2016	Prenatal	Not performed	Hysterectomy and conservative surgery	342
Lee <sup>53</sup>	2017	United States	Retrospective	2005-2015	Prenatal and at the time of CD	Not performed	Hysterectomy and conservative surgery	21
Pala <sup>54</sup>	2017	Turkey	Retrospective	2012-2016	NR	Not performed	Hysterectomy	36

Chaudhari <sup>55</sup>	2017	India	Retrospective	2012-2014	Prenatal	Not performed	Hysterectomy and conservative surgery	30
Karaman <sup>56</sup>	2016	Turkey	Retrospective	2013-2016	Prenatal	Not performed	Conservative surgery	12
Camuzcuoglu <sup>57</sup>	2015	Turkey	Retrospective	2009-2014	Prenatal	Not performed	Hysterectomy	58
Fitzpatrick <sup>58</sup>	2015	United Kingdom	Retrospective	2010-2011	Prenatal and at the time of CD	Not performed	Hysterectomy and conservative surgery	134
Norris <sup>59</sup>	2015	Australia	Retrospective	2009-2013	Prenatal and at the time of CD	Performed	Hysterectomy and conservative surgery	49
Shabana <sup>60</sup>	2015	Egypt	Retrospective	2011-2014	Prenatal and at the time of CD	Not performed	Conservative surgery	71
Thurn <sup>61</sup>	2015	Denmark, Finland, Iceland, Norway, and Sweden	Retrospective	2009-2012	Prenatal and at the time of CD	Not performed	Hysterectomy and conservative surgery	205
Shamshirsaz <sup>62</sup>	2014	United States	Retrospective					
Alchalabi <sup>63</sup>	2014	Jordan	Retrospective	2003-2012	Prenatal and at the time of CD	Not performed	Hysterectomy	23
Asicioglu <sup>64</sup>	2014	Turkey	Retrospective	2005-2010	Prenatal and at the time of CD	Not performed	Hysterectomy and conservative surgery	46
Brookfield <sup>65</sup>	2014	United States	Retrospective	1999-2002	NR	Not performed	Hysterectomy	77
Cali <sup>66</sup>	2014	Italy	Retrospective	2009-2013	Prenatal	Performed	Hysterectomy	43
Woldu <sup>67</sup>	2014	United States	Retrospective	2000-2011	Prenatal and at the time of CD	Performed	Hysterectomy	83
Chantraine <sup>68</sup>	2013	Belgium	Retrospective	1998-2011	Prenatal and at the time of CD	Not performed	Hysterectomy and conservative surgery	66
Chung <sup>69</sup>	2013	China	Retrospective	2005-2011	Prenatal and at the time of CD	Not performed	Hysterectomy and conservative surgery	15
Guleria <sup>70</sup>	2013	India	Retrospective	2001-2010	Prenatal and at the time of CD	Not performed	Hysterectomy and conservative surgery	56
Eller <sup>71</sup>	2011	United States	Retrospective	1996-2008	NR	Not performed	Hysterectomy	141
Meyer <sup>72</sup>	2011	United Kingdom	Retrospective	2008-2010	Prenatal	Not performed	Conservative management	12
Tikkanen <sup>73</sup>	2011	Finland	Retrospective	1998-2010	Prenatal and at the time of CD	Not performed	Hysterectomy and conservative surgery	44
Sultana <sup>74</sup>	2011	India	Retrospective	2008-2010	Prenatal	Not performed	Hysterectomy	32

Angstmann <sup>75</sup>	2010	Australia	Prospective	2001-2009	Prenatal and at the time of CD	Performed	Hysterectomy	26
Hoffman <sup>76</sup>	2010	United States	Retrospective	2003-2009	Prenatal and at the time of CD	Performed	Hysterectomy	29
Senthiles <sup>77</sup>	2010	France	Retrospective	1993-2007	Prenatal and at the time of CD	Not performed	Conservative surgery	167
Warshak <sup>78</sup>	2010	United States	Retrospective	1990-2008	Prenatal and at the time of CD	Not performed	Hysterectomy	99
Wright <sup>79</sup>	2010	United States	Retrospective	1998-2007	NR	Not performed	Hysterectomy	1798



**Table 2.** Quality assessment of the included studies according to Newcastle-Ottawa scale (NOS)

<b>Authors</b>	<b>Year</b>	<b>Selection</b>	<b>Comparability</b>	<b>Outcome</b>
Dawood <sup>18</sup>	2022	★★★	★★	★★
Kuznetsova <sup>19</sup>	2022	★★	★★	★★
Munoz <sup>20</sup>	2022	★★	★★	★★
Overton <sup>21</sup>	2022	★★	★★	★★
Pavon-Gomez <sup>22</sup>	2022	★★★	★★	★★
Scaglione <sup>23</sup>	2022	★★★	★★	★★
Senthiles <sup>24</sup>	2022	★★	★	★
Smith <sup>25</sup>	2022	★★	★★	★
Taskeen <sup>26</sup>	2022	★★	★	★
Xin <sup>27</sup>	2022	★	★	★
Bakacak <sup>28</sup>	2021	★★★	★★	★★
Erfani <sup>29</sup>	2021	★★	★★	★★
Matsuzaki <sup>30</sup>	2021	★★	★★	★★
Morlando <sup>31</sup>	2021	★★	★★	★★
Perveen <sup>32</sup>	2021	★★★	★★	★★
Soleymanimajd <sup>33</sup>	2021	★★★	★★	★★
Udden <sup>34</sup>	2021	★★	★	★
van Beekhuizen <sup>35</sup>	2021	★★	★★	★
Chahal <sup>36</sup>	2020	★★	★	★
Dall' Asta <sup>37</sup>	2020	★★	★★	★★
Nisar <sup>38</sup>	2020	★★	★★	★★
Saha <sup>39</sup>	2020	★★★	★★	★★
Celik <sup>40</sup>	2019	★★★	★★	★★
Crocetto <sup>41</sup>	2019	★★	★	★
Dawood <sup>42</sup>	2019	★★	★★	★
Nieto- Calvache <sup>43</sup>	2019	★★	★	★
Sak <sup>44</sup>	2019	★	★	★

Zuckerwise <sup>45</sup>	2019	★★★	★★	★★
Marcellin <sup>46</sup>	2018	★★	★★	★★
Meller <sup>47</sup>	2018	★★	★★	★★
Ozcan <sup>48</sup>	2018	★★	★★	★★
Shmakov <sup>49</sup>	2018	★★★	★★	★★
Thabet <sup>50</sup>	2018	★★★	★★	★★
Zhao <sup>51</sup>	2018	★★	★	★
Alanwar <sup>52</sup>	2017	★★	★★	★
Lee <sup>53</sup>	2017	★★	★	★
Pala <sup>54</sup>	2017	★★	★★	★★
Chaudhari <sup>55</sup>	2017	★★	★★	★★
Karaman <sup>56</sup>	2016	★★★	★★	★★
Camuzcuoglu <sup>57</sup>	2015	★★★	★★	★★
Fitzpatrick <sup>58</sup>	2015	★★	★	★
Norris <sup>59</sup>	2015	★★	★★	★
Shabana <sup>60</sup>	2015	★★	★	★
Thurn <sup>61</sup>	2015	★	★	★
Shamshirsaz <sup>62</sup>	2014			
Alchalabi <sup>63</sup>	2014	★★★	★★	★★
Asicioglu <sup>64</sup>	2014	★★	★★	★★
Brookfield <sup>65</sup>	2014	★★	★★	★★
Cali <sup>66</sup>	2014	★★	★★	★★
Woldu <sup>67</sup>	2014	★★★	★★	★★
Chantraine <sup>68</sup>	2013	★★★	★★	★★
Chung <sup>69</sup>	2013	★★	★	★
Guleria <sup>70</sup>	2013	★★	★★	★
Eller <sup>71</sup>	2011	★★	★	★
Meyer <sup>72</sup>	2011	★★	★	★
Tikkanen <sup>73</sup>	2011	★★	★★	★

Sultana <sup>74</sup>	2011	★★	★	★
Angstmann <sup>75</sup>	2010	★★★	★★	★★
Hoffman <sup>76</sup>	2010	★★	★★	★★
Senthiles <sup>77</sup>	2010	★★	★★	★★
Warshak <sup>78</sup>	2010	★★	★★	★★
Wright <sup>79</sup>	2010	★★★	★★	★★

A study can be awarded a maximum of one star for each numbered item within the Selection and Outcome categories. A maximum of two stars can be given for Comparability.

**Table 3.** Pooled proportions of adverse urological outcomes in women undergoing surgery for placenta accreta spectrum (PAS) disorders

<b>Outcome</b>	<b>Studies</b>	<b>Women</b>	<b>Pooled proportions (95% CI)</b>	<b>I<sup>2</sup> (%)</b>
<i>All cases</i>				
All urologic complications	49	1102/11618	15.29 (13.00-17.72)	87.1
Cystotomy (overall)	42	512/11286	13.02 (9.24-17.34)	96.5
Intentional cystotomy	21	21/1239	5.58 (2.74-9.34)	82.6
Unintentional cystotomy	21	38/1239	7.40 (4.34-11.18)	78.5
Ureteral damage	21	31/1391	2.45 (1.35-3.86)	47.9
Ureteral or bladder fistula	26	14/1814	1.44 (0.86-2.17)	21.8
<i>Women undergoing hysterectomy</i>				
All urologic complications	27	602/3411	19.36 (16.25-22.67)	69
Cystotomy (overall)	25	546/3379	17.05 (14.05-20.27)	70.2
Intentional cystotomy	15	129/1015	8.69 (4.79-13.61)	79.7
Unintentional cystotomy	15	102/1015	9.27 (5.21-14.36)	80.1
Ureteral damage	21	44/3098	1.80 (1.21-2.51)	12.6
Ureteral or bladder fistula	19	7/977	1.81 (1.00-2.88)	14.5
<i>Women undergoing conservative surgery or management</i>				
All urologic complications	14	99/930	12.22 (7.54-17.83)	79.9
Cystotomy (overall)	14	83/930	9.58 (5.68-14.37)	77
Intentional cystotomy	9	10/413	2.86 (0.67-6.51)	58.7
Unintentional cystotomy	9	21/413	7.28 (2.23-14.92)	79.6
Ureteral damage	13	14/839	2.05 (0.61-4.29)	65.8
Ureteral or bladder fistula	10	1/625	0.42 (0.006-1.08)	0

**Table 4.** Pooled proportions of adverse urological outcomes according to the severity of PAS at histopathology (placenta accreta-increta and percreta respectively)

<b>Outcome</b>	<b>Studies</b>	<b>Women</b>	<b>Pooled proportions (95% CI)</b>	<b>I<sup>2</sup> (%)</b>
<b><i>Placenta accreta-increta (all interventions)</i></b>				
All urologic complications	7	436/7058	9.42 (5.42-14.40)	66.7
Cystotomy (overall)	5	27/6964	5.53 (0.56-15.13)	0
Intentional cystotomy	3	6/69	6.50 (0.17-20.89)	60.2
Unintentional cystotomy	3	3/69	5.08 (0.026-11.80)	68.1
Ureteral injury	4	2/192	1.33 (0.07-4.11)	23.1
Ureteral or bladder fistula	4	0/175	0 (0-1.97)	0
<b><i>Placenta accreta-increta (Hysterectomy)</i></b>				
All urologic complications	3	28/248	13.72 (5.26-25.32)	75.2
Cystotomy (overall)	2	14/83	17.61 (10.26-26.4)	0
Intentional cystotomy	2	6/65	6.56 (0.06-26.59)	79.8
Unintentional cystotomy	2	3/65	5.17 (0.77-27.0)	84
Ureteral injury	2	2/83	3.05 (0.47-7.76)	0
Ureteral or bladder fistula	1	-	-	-
<b><i>Placenta percreta (all interventions)</i></b>				
All urologic complications	9	360/1292	38.52 (21.63-56.99)	93.7
Cystotomy (overall)	7	132/1257	21.97 (5.43-45.52)	96.2
Intentional cystotomy	5	20/146	11.47 (2.03-27.15)	80.4
Unintentional cystotomy	5	6/146	4.47 (1.71-8.42)	1.4
Ureteral injury	6	6/197	3.56 (0.92-7.81)	36.6
Ureteral or bladder fistula	5	5/163	3.81 (1.44-7.24)	0
<b><i>Placenta percreta (Hysterectomy)</i></b>				
All urologic complications	3	68/182	37.51 (30.62-44.66)	0.5
Cystotomy (overall)	2	17/55	30.06 (14.04-49.10)	53.4
Intentional cystotomy	2	16/55	27.15 (8.35-51.76)	72.2

Unintentional cystotomy	2	1/55	2.55 (0.10-10.54)	38.8
Ureteral injury	2	4/55	8.61 (2.76-17.28)	0
Ureteral or bladder fistula	1	-	-	-
<b><i>Placenta percreta (conservative management)</i></b>				
All urologic complications	3	11/91	12.72 (6.75-20.23)	0
Cystotomy (overall)	3	10/91	11.70 (5.99-19.00)	0
Intentional cystotomy	3	4/91	5.18 (1.62-10.59)	0
Unintentional cystotomy	3	6/91	7.53 (3.07-13.76)	0
Ureteral injury	3	0/91	0 (0-3.28)	0
Ureteral or bladder fistula	3	1/91	2.09 (0.19-5.97)	0

**Table 5.** Pooled proportions of adverse urological outcomes in women undergoing emergency and planned surgery for placenta accreta spectrum (PAS) disorders

<b>Outcome</b>	<b>Studies</b>	<b>Women</b>	<b>Pooled proportions (95% CI)</b>	<b>I<sup>2</sup> (%)</b>
<b><i>Planned intervention</i></b>				
All urologic complications	6	56/477	15.44 (8.11-24.61)	77.8
Cystotomy (overall)	2	16/268	10.73 (0.45-31.89)	87.2
Intentional cystotomy	-	-	-	-
Unintentional cystotomy	-	-	-	-
Ureteral injury	4	4/289	2.23 (0.13-6.80)	47.4
Ureteral or bladder fistula	4	1/289	0.66 (0.06-1.92)	0
<b><i>Emergency intervention</i></b>				
All urologic complications	5	82/289	24.61 (12.98-38.53)	87.9
Cystotomy (overall)	-	-	-	-
Intentional cystotomy	-	-	-	-
Unintentional cystotomy	-	-	-	-
Ureteral injury	2	1/160	1.03 (0.006-3.17)	0
Ureteral or bladder fistula	2	0/160	0 (0-1.71)	0



### PRISMA 2009 Flow Diagram

